玻璃体腔内注射康柏西普治疗非缺血型RVO的短期疗效观察

SHORT-TERM EFFICACY OF INTRAVITREAL INJECTION OF CONBERCEPT IN THE TREATMENT OF NON-ISCHEMIC RVO

目的探究玻璃体腔内注射康柏西普治疗非缺血型视网膜静脉堵塞(RVO)的短期临床疗效。方法回顾性分析2015年3月—2017年3月42例于我院就诊并确诊为非缺血型RVO患者的临床资料,全部患者采用玻璃体腔内注射康柏西普眼用注射液0.05 ml治疗。比较患者治疗前后的最佳矫正视力(BCVA)和黄斑中心视网膜厚度(CMT),并观察治疗后患者不良反应及并发症发生情况。结果42例患者42眼中,有13眼行1次注射,有19眼行2次注射,有10眼行3次注射。治疗前,患者最小视力分辨率的对数值(log VA)为(0.61±0.15),首次注射后1个月的log VA为(0.39±0.10),与注射前比较,log VA差异有统计学意义(t=7.909,P=0.000),第一次注射后1个月、2个月及6个月的log VA比较差异有统计学意义(F=15.349,P=0.000),且两两比较,差异有统计学意义(P<0.05)。治疗前,患者初始CMT为(538.46±114.76)μm,首次注射后1周的CMT为(284.76±65.26)μm,与注射前比较,CMT差异有统计学意义(t=12.454,P=0.000),第一次注射后,随访6个月,仅有4例(9.52%)出现一次性眼压过高,未见其他不良反应或并发症。结论采用玻璃体腔内注射康柏西普治疗非缺血型RVO短期疗效明确,能明显提高患者视力,降低患者CMT,且安全性高。

Objective To explore the short-term clinical efficacy of intravitreal injection of Conbercept in the treatment of non-ischemic RVO.Methods The clinical data of forty-two patients diagnosed as non-ischemic RVO in Suzhou Science Technology Town Hospital Affiliated to Nanjing Medical University from March 2015 to March 2017 were retrospectively analyzed.All patients were treated with intravitreal injection of 0.05 ml Conbercept ophthalmic injection.The best corrected visual acuity(BCVA)and central macular thickness(CMT)were compared among patients before and after treatment,and the occurrence of adverse reactions and complications were observed after treatment.Results Among 42 eyes of 42 patients,13 eyes were given 1 injection,and 19 eyes were given 2 injections and 10 eyes for 3 injections.Before treatment,the logarithm of minimum visual acuity(log VA)was(0.61±0.15),and the log VA at 1 month after first injection was(0.39±0.10).Compared with before injection,the difference in log VA was statistically significant(t=7.909,P=0.000),and there were statistically significant differences in log VA at 1 month,2 months and 6 months after first injection(F=15.349,P=0.000),and there were statistically significant differences in the comparison between any two(P<0.05).Before treatment,the initial CMT was(538.46±114.76)μm,and the CMT at 1 week after first injection was(284.76±65.26)μm.Compared with before injection,the difference in CMT was statistically significant(t=12.454,P=0.000).After first injection,6-month follow-up was performed on patients,and there was only 4 cases(9.52%)with one-time high intraocular pressure,and there were no other adverse reactions or complications.Conclusion Intravitreal injection of Conbercept has definite short-term efficacy on non-ischemic RVO,and it can significantly improve the visual acuity and decrease the CMT,and it has high safety.